Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. BWAY
stocks logo

BWAY

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Intellectia AI SwingMax
Intellectia AI SwingMax

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
14.02M
+22.81%
0.048
+18.75%
14.32M
+24.09%
0.045
+125%
15.32M
+21.24%
0.055
+10%
Estimates Revision
The market is revising Upward the revenue expectations for BrainsWay Ltd. (BWAY) for FY2025, with the revenue forecasts being adjusted by 1.39% over the past three months. During the same period, the stock price has changed by 8.08%.
Revenue Estimates for FY2025
Revise Upward
up Image
+1.39%
In Past 3 Month
EPS Estimates for FY2025
Revise Downward
down Image
-1.89%
In Past 3 Month
Stock Price
Go Up
up Image
+8.08%
In Past 3 Month
Wall Street analysts forecast BWAY stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BWAY is 20.00 USD with a low forecast of 18.00 USD and a high forecast of 23.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
3 Analyst Rating
Wall Street analysts forecast BWAY stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BWAY is 20.00 USD with a low forecast of 18.00 USD and a high forecast of 23.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
3 Buy
0 Hold
0 Sell
Strong Buy
Current: 17.130
sliders
Low
18.00
Averages
20.00
High
23.00
Current: 17.130
sliders
Low
18.00
Averages
20.00
High
23.00
H.C. Wainwright
H.C. Wainwright
Buy
maintain
$17 -> $18
2025-11-13
Reason
H.C. Wainwright
H.C. Wainwright
Price Target
$17 -> $18
2025-11-13
maintain
Buy
Reason
H.C. Wainwright raised the firm's price target on Brainsway to $18 from $17 and keeps a Buy rating on the shares. The firm notes BrainsWay announced that the FDA had granted a label expansion for its deep transcranial magnetic stimulation system. Expanded FDA clearance makes Deep TMS available as an adjunct therapy for adolescents aged 15-21 with major depressive disorder. Wainwright notes this was achieved a scant two months after the FDA granted expanded clearance to include an accelerated treatment protocol for MDD and patients with comorbid anxiety symptoms.
Ladenburg
Jeffrey Cohen
Buy
maintain
$19
2025-11-12
Reason
Ladenburg
Jeffrey Cohen
Price Target
$19
2025-11-12
maintain
Buy
Reason
Ladenburg analyst Jeffrey Cohen raised the firm's price target on Brainsway to $19 from $18.60 and keeps a Buy rating on the shares post the Q3 report. The firm cites the company's growth trajectory and improved profitability expectations for the target bump.
Northland
Carl Byrnes
Outperform
maintain
$19 -> $23
2025-11-12
Reason
Northland
Carl Byrnes
Price Target
$19 -> $23
2025-11-12
maintain
Outperform
Reason
Northland analyst Carl Byrnes raised the firm's price target on Brainsway to $23 from $19 and keeps an Outperform rating on the shares. BrainsWay's fundamentals continue to strengthen with 70% of recent system placements structured as multi-year lease agreements, the analyst tells investors.
H.C. Wainwright
Buy
upgrade
$16 -> $17
2025-08-14
Reason
H.C. Wainwright
Price Target
$16 -> $17
2025-08-14
upgrade
Buy
Reason
H.C. Wainwright raised the firm's price target on Brainsway to $17 from $16 and keeps a Buy rating on the shares. The firm expects accelerating growth for Brainsway in the coming quarters following the in-line Q2 report.
Northland
Outperform
upgrade
$15 -> $19
2025-08-14
Reason
Northland
Price Target
$15 -> $19
2025-08-14
upgrade
Outperform
Reason
Northland raised the firm's price target on Brainsway to $19 from $15 and keeps an Outperform rating on the shares. BrainsWay beat expectations in Q2 and fundamentals "continue to strengthen," the analyst tells investors in a post-earnings note.
HC Wainwright & Co.
Raghuram Selvaraju
Strong Buy
Reiterates
$16
2025-03-12
Reason
HC Wainwright & Co.
Raghuram Selvaraju
Price Target
$16
2025-03-12
Reiterates
Strong Buy
Reason
See All Ratings

Valuation Metrics

The current forward P/E ratio for Brainsway Ltd (BWAY.O) is 74.48, compared to its 5-year average forward P/E of 34.52. For a more detailed relative valuation and DCF analysis to assess Brainsway Ltd 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
34.52
Current PE
74.48
Overvalued PE
122.05
Undervalued PE
-53.00

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-2.42
Current EV/EBITDA
24.29
Overvalued EV/EBITDA
10.82
Undervalued EV/EBITDA
-15.65

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
Overvalued
5Y Average PS
3.25
Current PS
5.44
Overvalued PS
4.65
Undervalued PS
1.85
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %
N/A
ROIC

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
AI Stock Picker
AI Stock Picker

BWAY News & Events

Events Timeline

(ET)
2025-11-17
07:40:41
Brainsway Initiates First Trial of Deep TMS 360 System for Alcohol Use Disorder
select
2025-11-13 (ET)
2025-11-13
06:06:18
FDA Approves Brainsway's Deep TMS Device for Major Depressive Disorder
select
2025-11-11 (ET)
2025-11-11
07:32:45
Brainsway Adjusts FY25 Revenue Forecast to $51M-$52M, Slightly Up from $50M-$52M; Consensus at $50.96M
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
1.0
11-25Newsfilter
BrainsWay to Host Virtual Analyst & Investor Day on December 1, 2025
  • Strategic Investor Day: BrainsWay will host a virtual Analyst & Investor Day on December 1, 2025, where management will highlight the company's growth strategy, potentially attracting investor interest in its Deep TMS technology market potential.
  • Expert Participation: The event will feature Dr. Owen Scott Muir, Chief Medical Officer of Radial, who will share his clinical experience with Deep TMS, emphasizing the technology's importance in addressing mental health needs, which may enhance the company's authority in the industry.
  • Clinical Innovation Showcase: BrainsWay will present its patented Deep TMS treatment and the potential impact of its accelerated protocol aimed at improving symptoms of various mental health issues, including depression and OCD, further solidifying its market leadership.
  • Q&A Session Arrangement: A live question and answer session will follow the formal presentations, providing attendees with an opportunity to interact with management, potentially boosting investor confidence in the company's future developments.
[object Object]
Preview
9.0
11-13Newsfilter
BrainsWay Obtains FDA Approval for Deep TMS™ as Additional Treatment for Major Depressive Disorder in Teens Aged 15 to 21

  • FDA Approval: BrainsWay Ltd. announced that the FDA has expanded the label for its Deep TMS™ system to include treatment for adolescents aged 15 to 21 with major depressive disorder (MDD), addressing a critical gap in mental health care for this age group.

  • Clinical Evidence: The FDA's clearance was supported by a substantial dataset from 1,120 adolescents treated across 35 centers, showing significant improvements in depressive and anxiety symptoms after 36 treatment sessions.

  • Market Impact: This approval allows BrainsWay to treat both adults and adolescents with the same Deep TMS™ system, potentially reaching a significant number of the estimated 5 million adolescents in the U.S. who have experienced a major depressive episode.

  • Company Commitment: BrainsWay is dedicated to advancing noninvasive neurostimulation treatments and is actively conducting clinical trials for various psychiatric and neurological disorders, reinforcing its position as a leader in evidence-based mental health therapies.

[object Object]
Preview
4.0
11-13Benzinga
Northland Capital Markets Reaffirms Outperform Rating for BrainsWay, Increases Price Target to $23

  • Real-time Intelligence: Benzinga Pro offers the fastest news alerts for traders to stay updated on market movements.

  • Exclusive Stories: The platform provides unique stories generated by Benzinga reporters, enhancing the trading experience for its users.

  • Community of Traders: Over 10,000 serious traders are part of the Benzinga Pro community, sharing insights and strategies.

  • Market Winning Tools: Benzinga Pro equips traders with tools and information to improve their chances of success in the stock market.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Brainsway Ltd (BWAY) stock price today?

The current price of BWAY is 17.13 USD — it has decreased -0.35 % in the last trading day.

arrow icon

What is Brainsway Ltd (BWAY)'s business?

Brainsway Ltd is an Israel-based company engaged in the development and marketing of medical devices for the treatment of various neurological and psychopathological disorders. The Company primarily offers Transcranial Magnetic Stimulation (TMS) system, a medical device that enables direct non-invasive activation of deep brain structures. Its TMS system uses magnetic pulses to stimulate neurons and consequently modulates the physiological activity of the brain. TMS system is used in various clinical applications including: major depressive disorders, obsessive-compulsive disorder, smoking addiction and others various psychiatric, neurological, and addiction disorders.

arrow icon

What is the price predicton of BWAY Stock?

Wall Street analysts forecast BWAY stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BWAY is 20.00 USD with a low forecast of 18.00 USD and a high forecast of 23.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Brainsway Ltd (BWAY)'s revenue for the last quarter?

Brainsway Ltd revenue for the last quarter amounts to 13.51M USD, increased 28.66 % YoY.

arrow icon

What is Brainsway Ltd (BWAY)'s earnings per share (EPS) for the last quarter?

Brainsway Ltd. EPS for the last quarter amounts to 0.04 USD, increased 100.00 % YoY.

arrow icon

What changes have occurred in the market's expectations for Brainsway Ltd (BWAY)'s fundamentals?

The market is revising Upward the revenue expectations for BrainsWay Ltd. (BWAY) for FY2025, with the revenue forecasts being adjusted by 1.39% over the past three months. During the same period, the stock price has changed by 8.08%.
arrow icon

How many employees does Brainsway Ltd (BWAY). have?

Brainsway Ltd (BWAY) has 120 emplpoyees as of December 05 2025.

arrow icon

What is Brainsway Ltd (BWAY) market cap?

Today BWAY has the market capitalization of 335.15M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free